Bladder disease is the tenth most normal malignant growth around the world. The analysis and follow-up of patients require exorbitant obtrusive strategies and because of these costs, bladder disease keeps on being one of the costly malignancies. Early determination is pivotal in bladder disease for what it's worth in different tumors; in this way, non-intrusive biomarkers for early conclusion are vital. The point of the investigation was to analyze urinary insulin-like development factor 2 (IGF-2) levels in persistent pee tests and decide the capability of IGF-2 as a marker for the presence of urothelial carcinoma of the bladder (UCB). Techniques: 50 patients with bladder disease and 20 solid controls. Quantitative constant converse tran‌scription polymerase chain response (qRT-PCR) was led to quantify the IGF-2 articulation levels in pee of patients with bladder malignant growth and sound con‌trols. Results: patients with UCB have essentially raised degrees of urinary IGF-2.